Literature DB >> 30567994

Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.

Laurence Meyer1,2, Francis Barin3,4, Mélanie Bouvin-Pley3, Maxime Beretta3, Alain Moreau3, Emmanuelle Roch3, Asma Essat1, Cécile Goujard1,2, Marie-Laure Chaix5,6, Nathalie Moiré7, Loïc Martin8, Martine Braibant9.   

Abstract

We showed previously that during the HIV/AIDS epidemic, the envelope glycoprotein (Env) of HIV-1, and in particular, the gp120 subunit, evolved toward an increased resistance to neutralizing antibodies at a population level. Here, we considered whether the antigenic evolution of the HIV-1 Env is associated with modifications of its functional properties, focusing on cell entry efficacy and interactions with the receptor and coreceptors. We tested the infectivity of a panel of Env-pseudotyped viruses derived from patients infected by subtype B viruses at three periods of the epidemic (1987 to 1991, 1996 to 2000, and 2006 to 2010). Pseudotyped viruses harboring Env from patients infected during the most recent period were approximately 10-fold more infectious in cell culture than those from patients infected at the beginning of the epidemic. This was associated with faster viral entry kinetics: contemporary viruses entered target cells approximately twice as fast as historical viruses. Contemporary viruses were also twice as resistant as historical viruses to the fusion inhibitor enfuvirtide. Resistance to enfuvirtide correlated with a resistance to CCR5 antagonists, suggesting that contemporary viruses expanded their CCR5 usage efficiency. Viruses were equally captured by DC-SIGN, but after binding to DC-SIGN, contemporary viruses infected target cells more efficiently than historical viruses. Thus, we report evidence that the infectious properties of the envelope glycoprotein of HIV-1 increased during the course of the epidemic. It is plausible that these changes affected viral fitness during the transmission process and might have contributed to an increasing virulence of HIV-1.IMPORTANCE Following primary infection by HIV-1, neutralizing antibodies (NAbs) exert selective pressure on the HIV-1 envelope glycoprotein (Env), driving the evolution of the viral population. Previous studies suggested that, as a consequence, Env has evolved at the HIV species level since the start of the epidemic so as to display greater resistance to NAbs. Here, we investigated whether the antigenic evolution of the HIV-1 Env is associated with modifications of its functional properties, focusing on cell entry efficacy and interactions with the receptor and coreceptors. Our data provide evidence that the infectious properties of the HIV-1 Env increased during the course of the epidemic. These changes may have contributed to increasing virulence of HIV-1 and an optimization of transmission between individuals.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  envelope; evolution; human immunodeficiency virus; infectivity

Mesh:

Substances:

Year:  2019        PMID: 30567994      PMCID: PMC6401426          DOI: 10.1128/JVI.01171-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

2.  Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.

Authors:  M A Vodicka; W C Goh; L I Wu; M E Rogel; S R Bartz; V L Schweickart; C J Raport; M Emerman
Journal:  Virology       Date:  1997-06-23       Impact factor: 3.616

3.  Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.

Authors:  Madhumita Mahalanabis; Pushpa Jayaraman; Toshiyuki Miura; Florencia Pereyra; E Michael Chester; Barbra Richardson; Bruce Walker; Nancy L Haigwood
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

4.  Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

Authors:  M Bouvin-Pley; M Morgand; L Meyer; C Goujard; A Moreau; H Mouquet; M Nussenzweig; C Pace; D Ho; P J Bjorkman; D Baty; P Chames; M Pancera; P D Kwong; P Poignard; F Barin; M Braibant
Journal:  J Virol       Date:  2014-09-17       Impact factor: 5.103

5.  Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection.

Authors:  Simon D W Frost; Terri Wrin; Davey M Smith; Sergei L Kosakovsky Pond; Yang Liu; Ellen Paxinos; Colombe Chappey; Justin Galovich; Jeff Beauchaine; Christos J Petropoulos; Susan J Little; Douglas D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-09       Impact factor: 11.205

6.  Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques.

Authors:  Brian Jameson; Frédéric Baribaud; Stefan Pöhlmann; Darlene Ghavimi; Frank Mortari; Robert W Doms; Akiko Iwasaki
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

7.  Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNA.

Authors:  Moussa Laanani; Jade Ghosn; Asma Essat; Adeline Melard; Rémonie Seng; Marine Gousset; Henri Panjo; Emmanuel Mortier; Pierre-Marie Girard; Cécile Goujard; Laurence Meyer; Christine Rouzioux
Journal:  Clin Infect Dis       Date:  2015-03-03       Impact factor: 9.079

8.  2014 Update of the drug resistance mutations in HIV-1.

Authors:  Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman
Journal:  Top Antivir Med       Date:  2014 Jun-Jul

9.  HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Authors:  Michael Roche; Martin R Jakobsen; Anne Ellett; Hamid Salimiseyedabad; Becky Jubb; Mike Westby; Benhur Lee; Sharon R Lewin; Melissa J Churchill; Paul R Gorry
Journal:  Retrovirology       Date:  2011-11-07       Impact factor: 4.602

Review 10.  The immune response during acute HIV-1 infection: clues for vaccine development.

Authors:  Andrew J McMichael; Persephone Borrow; Georgia D Tomaras; Nilu Goonetilleke; Barton F Haynes
Journal:  Nat Rev Immunol       Date:  2009-12-11       Impact factor: 53.106

View more
  4 in total

Review 1.  Impact of HIV-1 Diversity on Its Sensitivity to Neutralization.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Martine Braibant; Francis Barin
Journal:  Vaccines (Basel)       Date:  2019-07-25

2.  Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates.

Authors:  Julio C C Lorenzi; Pilar Mendoza; Yehuda Z Cohen; Lilian Nogueira; Christy Lavine; Joseph Sapiente; Marie Wiatr; Nelly R Mugo; Andrew Mujugira; Sinead Delany; Jairam Lingappa; Connie Celum; Michael S Seaman; Marina Caskey; Michel C Nussenzweig
Journal:  J Virol       Date:  2020-12-09       Impact factor: 5.103

Review 3.  HIV-1 Entry and Prospects for Protecting against Infection.

Authors:  Jean-François Bruxelle; Nino Trattnig; Marianne W Mureithi; Elise Landais; Ralph Pantophlet
Journal:  Microorganisms       Date:  2021-01-22

4.  Common evolutionary features of the envelope glycoprotein of HIV-1 in patients belonging to a transmission chain.

Authors:  Maxime Beretta; Julie Migraine; Alain Moreau; Asma Essat; Cécile Goujard; Marie-Laure Chaix; Aurélie Drouin; Mélanie Bouvin-Pley; Laurence Meyer; Francis Barin; Martine Braibant
Journal:  Sci Rep       Date:  2020-10-07       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.